Chidamide maintenance therapy in high-risk T-ALL/T-LBL after allo-HSCT: a prospective, single-center, single-arm study

Wenwen Guo; Yigeng Cao; Jia Liu; Xinhui Zheng; Mingyang Wang; Yawei Zheng; Xiaoyu Zhang; Weihua Zhai; Xin Chen; Rongli Zhang; Qiaoling Ma; Donglin Yang; Jialin Wei; Yi He; Aiming Pang; Sizhou Feng; Mingzhe Han; Erlie Jiang

doi:10.1038/s41409-023-02045-w

Chidamide maintenance therapy in high-risk T-ALL/T-LBL after allo-HSCT: a prospective, single-center, single-arm study

Bone Marrow Transplant. 2023 Oct;58(10):1163-1166. doi: 10.1038/s41409-023-02045-w. Epub 2023 Jul 20.

Authors

Wenwen Guo^#^{1

2}, Yigeng Cao^#^{1

2}, Jia Liu^{1

2}, Xinhui Zheng^{1

2}, Mingyang Wang^{1

2}, Yawei Zheng^{1

2}, Xiaoyu Zhang^{1

2}, Weihua Zhai^{1

2}, Xin Chen^{1

2}, Rongli Zhang^{1

2}, Qiaoling Ma^{1

2}, Donglin Yang^{1

2}, Jialin Wei^{1

2}, Yi He^{1

2}, Aiming Pang^{1

2}, Sizhou Feng^{1

2}, Mingzhe Han^{1

2}, Erlie Jiang^{3

4}

Affiliations

¹ State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China.
² Tianjin Institutes of Health Science, Tianjin, 301600, China.
³ State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China. doctor_eljiang@163.com.
⁴ Tianjin Institutes of Health Science, Tianjin, 301600, China. doctor_eljiang@163.com.

^# Contributed equally.

PMID: 37474728
DOI: 10.1038/s41409-023-02045-w

No abstract available

Publication types

Letter